The presented results are promising that the 80 kDa fragment of e-cadherin can be approved as a serum biomarker for prostate cancer, being detectable at early stages of disease before specific therapy is initiated and potentially providing additional prognostic information besides clinical and pathological data. Here, CDH1 is linked to Familial prostate cancer.